Drug Trial Radar · NCT00219232
An Open-label Extension to Evaluate the Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease
Last checked: Nov 20, 2026Latest source record: Feb 23, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
868
Actual
Start
Feb 2003
Primary completion
Jul 2006
Study completion Jul 2006
Sponsor
- Lead sponsor
- NovartisNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 22, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this research study is to evaluate, in the open-label extension phase, the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease
Conditions
- Alzheimer's Disease
Interventions
Rivastigmine Transdermal PatchDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and tolerability as measured by adverse events, vital signs and skin irritation for up to 28 weeks treatment
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.